Results: 14
Calcium sensing receptor hyperactivation through viral envelop protein E of SARS CoV2: A novel target for cardio‐renal damage in COVID‐19 infection.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 784, doi. 10.1002/ddr.21810
- By:
- Publication type:
- Article
Contribution of N‐heterocycles towards anti‐tubercular drug discovery (2014–2019); predicted and reengineered molecular frameworks.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 767, doi. 10.1002/ddr.21809
- By:
- Publication type:
- Article
Therapeutic delivery with V‐amylose.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 727, doi. 10.1002/ddr.21804
- By:
- Publication type:
- Article
Insights into antimicrobial peptides in fighting anthrax: A review.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 754, doi. 10.1002/ddr.21803
- By:
- Publication type:
- Article
Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 730, doi. 10.1002/ddr.21796
- By:
- Publication type:
- Article
Paeonol protects melanocytes against hydrogen peroxide‐induced oxidative stress through activation of Nrf2 signaling pathway.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 861, doi. 10.1002/ddr.21793
- By:
- Publication type:
- Article
Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 852, doi. 10.1002/ddr.21792
- By:
- Publication type:
- Article
Alpha‐lipoic acid: A promising adjuvant for nonsteroidal anti‐inflammatory drugs therapy with improved efficacy and gastroprotection.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 844, doi. 10.1002/ddr.21791
- By:
- Publication type:
- Article
Protection of clozapine‐induced oxidative stress and mitochondrial dysfunction by kaempferol in rat cardiomyocytes.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 835, doi. 10.1002/ddr.21790
- By:
- Publication type:
- Article
Design, synthesis, and structure–activity relationship study of O‐prenylated 3‐acetylcoumarins as potent inhibitors of soybean 15‐lipoxygenase.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 826, doi. 10.1002/ddr.21787
- By:
- Publication type:
- Article
A pharmacokinetic study of morphine‐6‐O‐sulfate in rat plasma and brain.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 802, doi. 10.1002/ddr.21785
- By:
- Publication type:
- Article
In silico design and synthesis of N‐arylalkanyl 2‐naphthamides as a new class of non‐purine xanthine oxidase inhibitors.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 789, doi. 10.1002/ddr.21782
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 725, doi. 10.1002/ddr.21695
- Publication type:
- Article
Soluble epoxide hydrolase inhibitor trifluoromethoxyphenyl‐3‐(1‐propionylpiperidin‐4‐yl)urea prevents hyperalgesia through regulating NLRC4 inflammasome‐related pro‐inflammatory and anti‐inflammatory signaling pathways in the lipopolysaccharide‐induced pain mouse model
- Published in:
- Drug Development Research, 2021, v. 82, n. 6, p. 815, doi. 10.1002/ddr.21786
- By:
- Publication type:
- Article